A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jaeger E, Mitrou PS (2010)

Publication Type: Journal article

Publication year: 2010

Journal

Leukemia & Lymphoma Informa Healthcare

Book Volume: 51

Pages Range: 447-455

Journal Issue: 3

DOI: 10.3109/10428190903580402

Abstract

The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is a need for improvement of treatment options. Patients with newly diagnosed (n27) or refractory/relapsed (n11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin. The overall response rate (ORR) was 61, with a complete response rate of 39. In newly diagnosed patients the ORR was 63, the median overall survival 25.9 months, and progression-free survival 11.8 months. In relapsed/refractory patients the median OS was 6.1 months. The most frequent grade 3/4 toxicities were leukopenia (95 of patients) and thrombocytopenia (58). Cytomegalovirus (CMV) reactivation occurred in 12 patients, but only two had CMV disease. Treatment-related deaths occurred in six newly diagnosed patients and one with relapsed/refractory disease. In conclusion, Campath-FCD is active in PTCL but is associated with significant toxicity and is, therefore, not recommended for use or further study. Further studies are warranted to investigate other approaches to combining alemtuzumab with chemotherapy for the treatment of PTCL. © 2010 Informa Healthcare USA, Inc.

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Eberhard Karls Universität Tübingen DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Regensburg DE Germany (DE) Krankenhaus Nordwest DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Philipps-Universität Marburg DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE)

How to cite

APA:

Weidmann, E., Hess, G., Chow, K.U., Krause, S.W., Subklewe, M., Kruse, J.,... Mitrou, P.S. (2010). A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leukemia & Lymphoma, 51(3), 447-455. https://doi.org/10.3109/10428190903580402

MLA:

Weidmann, Eckhart, et al. "A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas." Leukemia & Lymphoma 51.3 (2010): 447-455.

BibTeX: Download